Abstract
Current practice in the design and evaluation of epidemic control measures, including vaccination, is largely based on reproduction numbers (RNs), which represent prognostic indexes of long-term disease transmission, both in naïve populations (basic RN) and in the presence of prior exposure or interventions (effective RN). A standard control objective is to establish herd immunity, e.g., by immunizing enough susceptible individuals to achieve RN<1. However, attaining this goal is not sufficient to avoid transient outbreaks that, in the short term, might revamp epidemics by coalescence of subthreshold flare-ups.
Using reactivity analysis applied to a discrete SIR model with age-of-infection structure, we determine sufficient conditions to prevent transient epidemic dynamics and recurrent, non-periodic outbreaks due to imported cases. These conditions are based on fundamental infection characteristics, namely the average infectiousness clearance rate, the generation time distribution, and the RN.
We show that preventing subthreshold epidemicity requires stricter RN thresholds than simply maintaining RN< 1. Taking into account a wide spectrum of respiratory viral infections, epidemicity-curbing RN thresholds vary between 0.10 (rubella) and 0.51 (MERS), with a median of 0.26 close to the estimate of 0.24 for the ancestral SARS-CoV-2 virus. The portion of the population that needs to be included in containment efforts to avoid short-term outbreaks is considerably higher than herd immunity thresholds (HITs) based solely on the basic RN (e.g., 93% vs. 72% for ancestral SARS-CoV-2). We also find that subthreshold epidemicity is harder to prevent for pathogens with a longer mean generation time, smaller standard deviation of the generation time distribution, longer duration of infection, and higher RN.
Determining sufficient RN thresholds to prevent transient outbreaks is a key challenge in disease ecology, with practical consequences for the design of control measures, as the weaker RN reductions and HITs associated with customary control targets may prove ineffective in preventing potentially recurrent flare-ups. Due to its modest data requirements, our modeling framework may also have important implications for human and non-human diseases caused by emerging pathogens.
Data/Code This work has no associated primary data. The secondary data used to parameterize the model are described in Supporting Information (SI, section S1; see also SI References). The main code to perform discrete epidemicity analysis has been uploaded for review purposes; it will be made available on a public repository once the editorial process is completed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
L.M. acknowledges funding from the Italian Ministry of University and Research through via the project ``Epidemiological data assimilation and optimal control for short-term forecasting and emergency management of COVID-19 in Italy'' (FISR\_2020IP\_04249). C.T. and A.R. acknowledge funding from the Swiss National Science Foundation via the project "Optimal control of intervention strategies for waterborne disease epidemics" (200021-172578). A.R. acknowledges funding from Fondazione Cassa di Risparmio di Padova e Rovigo (Italy) through its grant 55722.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This work has no associated primary data. The secondary data used to parameterize the different viral respiratory infections are described in the Supporting Information.
